009420 — Hanall Biopharma Share News
0.000.00%
Last trade - 00:00- KR₩2tn
- KR₩2tn
- KR₩155bn
Brief: Hanall's Licensed Partner In China Enters Sublicense Agreement With Cspc To Further Accelerate Development Of Batoclimab
Caladrius soars as stockholders approve merger with Cend Therapeutics
Australia's Neuren Pharma soars as FDA accepts new drug application for review
Larimar surges on plan to resolve clinical hold on rare disease drug
Brief: Hanall Biopharma Reports Second Quarter 2022 Results And Provides Business Update
Australia's Imugene jumps on 'favourable' survival outcome in immunotherapy candidate trial
Australia's Imugene rises on approval to start trial for cancer treatment
Genocea Biosciences hits record low on strategic review, workforce reduction plan
Australia's Immuron hits over 2-month high on robust global sales
Gossamer Bio gains as UBS starts coverage with 'buy'
Stifel bullish on Imago BioSciences' lead drug potential; shares gain
4D Pharma surges on positive interim data from kidney cancer drug trial
Apellis jumps after favorable long-term data from eye disorder drug studies
Gracell Biotech slumps on delaying U.S. regulatory filing for lead drug
Abbvie gains on resolving arthritis drug litigation in U.S.
Ocugen falls as FDA declines to authorize COVID-19 shot for children
Ocugen jumps as FDA lifts clinical hold on COVID vaccine trial application
Larimar set to open at record low as FDA maintains clinical hold on trial
Aridis Pharma gains on Gates foundation funding for COVID-19 therapy